Cargando…

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer

Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when che...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosati, Gerardo, Montrone, Michele, Pacilio, Carmen, Colombo, Alfredo, Cicero, Giuseppe, Paragliola, Fernando, Vaia, Angelo, Annunziata, Luigi, Bilancia, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739901/
https://www.ncbi.nlm.nih.gov/pubmed/36498683
http://dx.doi.org/10.3390/jcm11237108
_version_ 1784847924089323520
author Rosati, Gerardo
Montrone, Michele
Pacilio, Carmen
Colombo, Alfredo
Cicero, Giuseppe
Paragliola, Fernando
Vaia, Angelo
Annunziata, Luigi
Bilancia, Domenico
author_facet Rosati, Gerardo
Montrone, Michele
Pacilio, Carmen
Colombo, Alfredo
Cicero, Giuseppe
Paragliola, Fernando
Vaia, Angelo
Annunziata, Luigi
Bilancia, Domenico
author_sort Rosati, Gerardo
collection PubMed
description Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients.
format Online
Article
Text
id pubmed-9739901
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97399012022-12-11 An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer Rosati, Gerardo Montrone, Michele Pacilio, Carmen Colombo, Alfredo Cicero, Giuseppe Paragliola, Fernando Vaia, Angelo Annunziata, Luigi Bilancia, Domenico J Clin Med Review Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients. MDPI 2022-11-30 /pmc/articles/PMC9739901/ /pubmed/36498683 http://dx.doi.org/10.3390/jcm11237108 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rosati, Gerardo
Montrone, Michele
Pacilio, Carmen
Colombo, Alfredo
Cicero, Giuseppe
Paragliola, Fernando
Vaia, Angelo
Annunziata, Luigi
Bilancia, Domenico
An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
title An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
title_full An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
title_fullStr An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
title_full_unstemmed An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
title_short An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
title_sort update on the role of anti-egfr in the treatment of older patients with metastatic colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739901/
https://www.ncbi.nlm.nih.gov/pubmed/36498683
http://dx.doi.org/10.3390/jcm11237108
work_keys_str_mv AT rosatigerardo anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT montronemichele anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT paciliocarmen anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT colomboalfredo anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT cicerogiuseppe anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT paragliolafernando anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT vaiaangelo anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT annunziataluigi anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT bilanciadomenico anupdateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT rosatigerardo updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT montronemichele updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT paciliocarmen updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT colomboalfredo updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT cicerogiuseppe updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT paragliolafernando updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT vaiaangelo updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT annunziataluigi updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer
AT bilanciadomenico updateontheroleofantiegfrinthetreatmentofolderpatientswithmetastaticcolorectalcancer